Quick Answer
Editas Medicine, Inc. reported Cash and Equivalents of $146.65 million for fiscal year 2025.
Editas Medicine, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $146.65M | +11.5% |
| 2024 | $131.54M | +6.4% |
| 2023 | $123.65M | -12.6% |
| 2022 | $141.52M | -30.5% |
| 2021 | $203.52M | +45.7% |
| 2020 | $139.68M | -41.4% |
| 2019 | $238.18M | +76.7% |
| 2018 | $134.78M | -8.1% |
| 2017 | $146.63M | -20.9% |
| 2016 | $185.32M | +29.4% |
| 2015 | $143.18M | +1247.8% |
| 2014 | $10.62M | +428.0% |
| 2013 | $2.01M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $165.65M | +72.9% | +19.6% |
| June 30, 2025 | $138.54M | +115.0% | -0.1% |
| March 31, 2025 | $138.69M | +100.3% | +5.4% |
| December 31, 2024 | $131.54M | +6.4% | +37.3% |
| September 30, 2024 | $95.83M | +16.1% | +48.7% |
| June 30, 2024 | $64.44M | -70.8% | -6.9% |
| March 31, 2024 | $69.23M | -46.3% | -44.0% |
| December 31, 2023 | $123.65M | -12.6% | +49.8% |
- Editas Medicine, Inc. showed an increase of +11.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Editas Medicine, Inc.’s cash and equivalents has grown by 7188.5% (from $2.01 million to $146.65 million).
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: